Daz A, Lpez-Grueso R, Gambini J, Monlen D, Mas-Bargues C, Abdelaziz KM, et al
Bit of Background These new classes of antiobesity medications (ie, the GLP-1 agonists and dual agonists), referred to in this article as weight management medications, arent really new.1-4 The basic science and pharmaceutical research and development to bring these to market began more than two decades ago when two scientists, Matthias Tschop, MD, and Richard DiMarchi, PhD, hypothesized that the actions of various gut hormones may offer safe and unprecedented weight loss
Mojsov et al., 1987
Researchers calibrated the CORE model with baseline characteristics from LEAD-1 and projected outcomes, including survival rates, cardiovascular, ophthalmic, and renal events incidence, and healthcare expenditures over 10-, 20-, and 30-year intervals (16)(17)
Informacin Adicional Mecanismo de accin LEVOCARNITINA constituyente natural de los tejidos animales, microorganismos y plantas
